XTX Topco Ltd Buys 43,221 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

XTX Topco Ltd boosted its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 110.7% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 82,276 shares of the company’s stock after buying an additional 43,221 shares during the quarter. XTX Topco Ltd’s holdings in Amneal Pharmaceuticals were worth $689,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of AMRX. Nantahala Capital Management LLC boosted its stake in Amneal Pharmaceuticals by 37.3% in the fourth quarter. Nantahala Capital Management LLC now owns 3,665,529 shares of the company’s stock valued at $29,031,000 after buying an additional 995,586 shares in the last quarter. BlackBarn Capital Partners LP boosted its stake in Amneal Pharmaceuticals by 18.2% in the fourth quarter. BlackBarn Capital Partners LP now owns 2,850,000 shares of the company’s stock valued at $22,572,000 after buying an additional 438,388 shares in the last quarter. Mariner LLC boosted its stake in Amneal Pharmaceuticals by 3,749.1% in the fourth quarter. Mariner LLC now owns 424,291 shares of the company’s stock valued at $3,360,000 after buying an additional 413,268 shares in the last quarter. Bank of America Corp DE boosted its stake in Amneal Pharmaceuticals by 218.8% in the fourth quarter. Bank of America Corp DE now owns 556,881 shares of the company’s stock valued at $4,410,000 after buying an additional 382,222 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Amneal Pharmaceuticals in the fourth quarter valued at about $2,946,000. 31.82% of the stock is owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock opened at $7.96 on Tuesday. The stock’s 50 day moving average is $7.95 and its 200 day moving average is $7.96. The firm has a market cap of $2.49 billion, a P/E ratio of -198.95 and a beta of 1.11. Amneal Pharmaceuticals, Inc. has a one year low of $6.50 and a one year high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Friday, May 2nd. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.05. The company had revenue of $695.42 million for the quarter, compared to analyst estimates of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 188.26% and a negative net margin of 0.46%. Equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AMRX has been the topic of a number of recent research reports. The Goldman Sachs Group initiated coverage on Amneal Pharmaceuticals in a research note on Friday, June 6th. They set a “buy” rating and a $12.00 price target on the stock. Wall Street Zen lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 13th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $11.60.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.